Enlivex Therapeutics
Formerly Tolarex
Macrophage Reprogramming Cell Therapies for Life-threatening Diseases
Startup Public Health Tech & Life Sciences Est. 2005
🌐 WebsiteLinkedInTwitterCareers
Total Raised
$74.9M
Public
Last Round
$15M
10 rounds
Investors
5
5 public
Team
4
11-50 employees
Confidence
91/100
News
135
articles
Patents
1
About
Enlivex Therapeutics is a clinical-stage company focused on macrophage reprogramming. The company intends to develop and commercialize a drug pipeline for macrophage reprogramming in solid cancers, sepsis, COVID-19, and other indications. The company's most advanced product candidate, Allocetra, was developed for the reprogramming of diseased macrophages in patients with sepsis or COVID-19, and has demonstrated positive safety, tolerability, and efficacy in several clinical trials. In March 2019, the company announced the completion of its merger with Tel Aviv-headquartered Bioblast Pharma. Following the reverse merger, Enlivex became a subsidiary of Bioblast, which was renamed Enlivex Therapeutics.
Classification
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Core Technology
BiologicalsCells
Target Customer
Healthcare & Life SciencesLife SciencesPharmaceuticalsBiotechnologyHealthcareProvidersPatients
Business Model
B2B
Tags
cell-therapyinflammatory-diseasescrohn's-diseasepharmaceuticalscancerimmunologyimmunotherapypharma-companieschronic-patientspatientsautoimmune-diseases
Funding & Events
Sep 2017
B Round $8M
Hadasit Bio-Holdings, Korea Investment Partners
May 2024
PIPE $15M
Undisclosed Investor(s)
May 2021
Non-equity $1.1M
Israel Innovation Authority
May 2019
Non-equity $1.1M
Israel Innovation Authority
May 2014
Debt Financing $7M
Hadasit Bio-Holdings, Shai Novik, Capital Point
Mar 2019
Exit Undisclosed
Jul 2019
Exit Undisclosed
Feb 2021
Exit $46M
Apr 2020
Non-equity $1.5M
Israel Innovation Authority
Apr 2019
Non-equity $1M
Israel Innovation Authority
Non-equity $1.2M
Israel Innovation Authority (Lead)
News (135)
Oct 28, 2025 · finance.yahoo.com
growth-positive
Enlivex Therapeutics to Present Phase IIa 3-month Data of Allocetra in Patients with Moderate-to-Severe Knee Osteoarthritis at the ACR Convergence 2025
Product StageFDA approved/pending approval
Oct 3, 2025 · finance.yahoo.com
growth-positive
Enlivex Therapeutics and Lantern Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Product StagePublic Trading
Sep 29, 2025 · finance.yahoo.com
growth-positive
D. Boral Capital to Host KOL Webinar With World Leading Experts Featuring Insights & Breakthroughs from Enlivex's Knee Osteoarthritis Program
Product Stage
Sep 19, 2025 · finance.yahoo.com
growth-positive
Enlivex Therapeutics and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Product Stage
Sep 14, 2025 · finance.yahoo.com
growth-negative
Will Enlivex Therapeutics (NASDAQ:ENLV) Spend Its Cash Wisely?
Sep 11, 2025 · finance.yahoo.com
growth-positive
Enlivex CEO Issues Letter to Shareholders Outlining Strategic Roadmap Following Positive Phase IIa Allocetra™ Results
Product Stage
Sep 9, 2025 · finance.yahoo.com
growth-positive
Enlivex Announces Issuance of New Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis
Product StageFDA approved/pending approval
Aug 19, 2025 · www.clinicaltrialsarena.com
growth-positive
Enlivex advances lead cell therapy to Phase IIb in osteoarthritis
Product Stage
Aug 18, 2025 · finance.yahoo.com
growth-positive
Enlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee Osteoarthritis
Product StageFDA approved/pending approval
Aug 14, 2025 · finance.yahoo.com
growth-positive
Enlivex to Present 3-Month Topline Data from Phase IIa Moderate/Severe Knee Osteoarthritis Trial on August 18 Webinar
Product Stage
Jul 28, 2025 · finance.yahoo.com
growth-positive
Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II Topline Data
Product Stage
Jun 13, 2025 · finance.yahoo.com
growth-positive
Enlivex Therapeutics and Foremost Clean Energy Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Product StagePartners
Jun 10, 2025 · finance.yahoo.com
growth-positive
Enlivex Therapeutics to Present Clinical Data of Allocetra in Osteoarthritis at EULAR 25 European Congress of Rheumatology
Product Stage
May 20, 2025 · finance.yahoo.com
growth-positive
Enlivex Selected to Present at Israeli BioMed 2025 Conference
Product Stage
Apr 23, 2025 · finance.yahoo.com
growth-positive
Enlivex Therapeutics to Showcase Allocetra’s Potential in Osteoarthritis at OARSI 2025 World Congress
Product Stage
Apr 22, 2025 · www.clinicaltrialsarena.com
growth-positive
Enlivex enrols all patients in Phase II stage of knee osteoarthritis trial
Product Stage
Apr 21, 2025 · finance.yahoo.com
growth-positive
Enlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis
Product Stage
Apr 7, 2025 · finance.yahoo.com
growth-negative
Is Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Invest In Growth?
Apr 3, 2025 · finance.yahoo.com
growth-positive
Enlivex Announces the Dosing of the First Patient in a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis
Product Stage
Mar 17, 2025 · finance.yahoo.com
growth-positive
Enlivex Receives Notice of Allowance for Chinese Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis
Product Stage
+ 115 more articles
Details
Product Stage
Clinical Trial
Employees
11-50
Exact Count
35
District
Center District
Founded
2005
Registrar
513736264
Crunchbase
enlivex-therapeutics
Locations
Einstein St 14, Nes Ziona, Israel
Links
Website
enlivex.com
LinkedIn
Profile
Twitter
Profile
Careers
Open positions
Admin
Last Update
Oct 28, 2025
Verified by
Yanina Wainscheinker
Missing
markets, not claimed
Team (4)
Shai Novik
Executive Chairman
Oren Hershkovitz
CEO
Prof. Dror Mevorach
Founder, Chief Scientific & Medical Officer
Founder
Shachar Shlosberger
CFO
Finder · Enlivex Therapeutics · 2026